Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity-Reference-Cited by-同舟云学术

Efficacy and immune modulation associated with the addition of IMiDs to Daratumumab backbone in multiple myeloma patients refractory to both drug classes: resetting synergistic activity

Published:2024-02-06 Issue:1 Volume:14 Page:
ISSN:2044-5385
Container-title:Blood Cancer Journal
language:en
Short-container-title:Blood Cancer J.

Author:

Kostopoulos Ioannis V.,Fotiou Despina^ORCID,Gavriatopoulou Maria^ORCID,Rousakis Pantelis,Ntanasis-Stathopoulos Ioannis^ORCID,Panteli Chrysanthi,Malandrakis Panagiotis,Migkou Magdalini,Angelis Nikolaos,Kanellias Nikolaos,Eleutherakis-Papaiakovou Evangelos,Theodorakakou Foteini,Krevvata Maria,Terpos Evangelos^ORCID,Dimopoulos Meletios-Athanasios^ORCID,Tsitsilonis Ourania^ORCID,Kastritis Efstathios^ORCID

Funder

Honoraria/ research support: Janssen, GSK, Pfizer, Sanofi.

Honoraria/ research support: Karyopharm X4 Pharmaceuticals, GSK, Takeda, Janssen, Amgen, Celgene/Genesis, Sanofi;

MK is a Janssen employee

Honoraria/ research support: Amgen, BMS, ASTRAZeneca, EUSA Pharma, GSK, Janssen, Menarini/Stemline, Pfizer, Sanofi, Takeda;

Honoraria/ research support: AbbVie, Amgen, Bristol Myers Squibb, BeiGene Inc, GSK, Janssen, Menarini, Regeneron, Sanofi, Takeda

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41408-024-00988-x.pdf

Reference15 articles.

1. Moreau P, Kumar SK, San Miguel J, Davies F, Zamagni E, Bahlis N, et al. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021;22:e105–18.

2. Dimopoulos MA, Richardson P, Lonial S. Treatment options for patients with heavily pretreated relapsed and refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2022;22:460–73.

3. Gandhi UH, Cornell RF, Lakshman A, Gahvari ZJ, McGehee E, Jagovsky MH, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33:2266–75.

4. Mateos MV, Weisel K, De Stefano V, Goldschmidt H, Delforge M, Mohty M, et al. LocoMMotion: a prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed and/or refractory multiple myeloma. Leukemia. 2022;36:1371–6.

5. Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, et al. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with daratumumab among refractory patients. Cancer. 2019;125:2991–3000.